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Volume 50, Number 2 Letters to the Editor 475that in addition to the volume of intraluminal thrombus, its
location and impact on the geometry of the arterial lumen can
affect the wall stress and ultimately result in variable pattern of
aneurysm growth. A prospective longitudinal is therefore required
to assess the changes in thrombus volume, resultant change in
lumen curvature, and pattern of aneurysm growth/expansion,
before we can say that tortuosity of lumen centerline is the key
determinant of increasing the aneurysm wall stress.
Another important area worth exploring is the material behav-
ior of intraluminal thrombus. It is most likely a non-homogeneous
material with a complex property. A large ex vivo experiment is
needed for future study in this area to improve our understanding
of aneurysm material properties and failure strength. This can help
in creating more realistic computational models, which could be
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Regarding “Risk-adjusted 30-day outcomes of carotid
stenting and endarterectomy: Results from the SVS
Vascular Registry”
We have read the study by Sidawy et al1 about 30-day out-
comes of carotid artery stenting (CAS) compared with endarterec-
tomy (CEA) with great interest. Unfortunately, we are forced to
conclude that major flaws in the study prevent drawing meaningful
conclusions from this observational cohort study. Although cohort
studies can sometimes be powerful tools in assessing treatment
effectiveness,2 the authors’ study fails to meet minimal standards
for such studies; most importantly, (1) complete and unbiased
follow-up of study end points, and (2) rigorous control for con-
founders.
The validity of the conclusions drawn from a study such as
theirs, with only 44% follow-up, is extremely limited. Those lost to
follow-up are likely to be less adherent to concomitant drug
therapy and are often more likely to have had complications; or in
contrast, sometimes those who are doing extremely well may waive
follow-up visits.3-5 In general, 80% follow-up in longitudinal stud-
ies is considered a minimum, and 90% follow-up is generally
feasible in short follow-up studies like that of Sidawy et al.1 This
study’s poor follow-up is made worse by the different follow-up
rates between groups, by the reliance on self-report, and by
the presence of systematic differences between CEA and CAS
follow-up, because Centers for Medicare and Medicaid Servicesrules require in-hospital results for CAS for recertification,
whereas there is no such mandate for CEA.
Furthermore, controlling for all potential confounders is al-
ways important in cohort studies, but particularly in those in which
the choice of intervention is heavily influenced by patient factors
(ie, “selection”).2 Those who are more frail or who have higher
surgical risk are generally much more likely to have a minimally
invasive procedure (CAS) instead of a surgery (CEA), and biases
due to such patient and provider selection are notoriously difficult
to adjust for in cohort studies, usually requiring special methods
such as instrumental variable analyses.2
The results of Sidawy et al are in conflict with several random-
ized controlled trials comparing these two interventions and re-
porting equivalence of the two interventions,6-9 even in the long-
term.6 Therefore, we suggest that the short-term differences found
in this observational cohort study with poor follow-up and likely
inadequate control for confounding do not provide useful evi-
dence on this important clinical topic.
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Reply
The authors appreciate the comments from Drs Meier and
Hayward indicating potential flaws in our article, the first being
lack of complete and unbiased follow-up and the second being
inability for rigorous control for confounders. These weaknesses
were already identified as issues inherent to a study based on
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August 2009476 Letters to the editorregistry data in the Discussion section of the article. As a major
point of clarification, this is not an observational cohort study but
rather a real-world patient registry.
With respect to the first issue of complete and unbiased
follow-up, Drs Meier and Hayward are correct in identifying
systematic differences, noting that the Center for Medicare and
Medicaid Services mandates in-hospital results only for carotid
artery stenting (CAS) and not carotid endarterectomy (CEA).
However, the Society for Vascular Surgery (SVS) Vascular Registry
(VR) was designed with this knowledge beforehand, and as a
condition of participation in VR, some centers agreed to enter
both interventions as well as follow-up.
The goal of the article was to report the results of the entire
VR, since it is the first large-scale registry that has available data on
the current practice application of CAS and CEA. Although the VR
does not have predefined visit intervals, it does rely on each
facility’s standards of care to capture the real-world experience,
including follow-up. As noted in the article, in-hospital and 30-day
comparisons were both reported. The in-hospital results were
reported on 100% of patients; and even in this comparison, the
results have shown, in this registry, the superiority of CEA.
With respect to rigorous controls for confounders, there are
several aspects to discuss. It is true that a great deal of selection bias
can be introduced in a real-world setting in which physicians are
allowed to choose which procedure better suits the best interest of
the patient. By definition, patients who receive CAS are going to be
of a higher risk than patients who receive CEA. Thus, because this
is a current clinical practice (real-world experience) registry, diver-
sity in the patient population is expected and cannot have “rigor-
ous control for confounders.” In an effort to adjust for these
confounders, the authors performed logistic regression using back-
wards elimination, as described in the manuscript. It had also been
suggested in another Letter to the Editor that propensity score
matching be used,1 for which the authors had responded that even
with using propensity matching, still CAS patients had worse
30-day outcomes than CEA patients.2
Drs Meier and Hayward also contend that the VR results are in
conflict with several randomized controlled trials (RCTs) compar-
ing CAS and CEA. Although some RCT results conflict with the
VR results, other RCTs, such as Endarterectomy versus Stenting in
Patients with Symptomatic Severe Carotid Stenosis (EVA-3S),3 are
not in disagreement. Rather, 30-day results of EVA-3S show worse
outcomes of CAS (9.6%) vs CEA (3.9%) than that reported from
VR, as do the 4-year results of EVA-3S.4 We would like to reiterate
the conclusion at the end of the article, that “The debate about the
interpretation of the results of this study as well as results of other
CAS studies will continue until randomized trials such as Interna-
tional Carotid Stenting Study (ICSS) in Europe and CREST in
North America are reported.”5
Anton N. Sidawy, MD, MPH
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Regarding “Improved outcomes are associated with
multilevel endovascular intervention involving the
tibial vessels compared with isolated tibial
intervention”
It was with great interest that we read the article by Sadek et
al.1 They concluded that patients who undergo multilevel inter-
vention involving the tibial vessels exhibit improved secondary
patency compared with those who undergo intervention for lesions
isolated to the tibial vessels. We wholeheartedly agree with their
opinion as well as their recommendation.
The authors reported that a comparison between single-level
intervention and multilevel intervention involving the infrapopli-
teal vasculature has never been performed. Actually, we first de-
scribed the importance of multilevel endovascular intervention
involving the infrapopliteal vasculature.2 Furthermore, we re-
ported the fact that more than one tibial artery vessel being treated
in the same setting could be an explanation for a better outcome or
improved results.
The aim for performing multilevel endovascular intervention
is to improve the runoff and, therefore, decrease the risk of
restenosis related to the fact that poor runoff was reported as a
variable predicting restenosis. We definitely need to be more
aggressive and treat all reachable lesions to improve clinical out-
comes of endovascular procedures. Multilevel lesions should not
be considered a limitation for an endovascular approach, and on
the contrary, as reported in this article and in our experience,
should prompt us to consider endovascular as a first-line procedure
in patients with critical limb ischemia.
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Regarding “Open-cell versus closed-cell stent design
differences in blood flow velocities after carotid
stenting”
Although several studies have suggested that stent placement
in the carotid artery alters its biomechanical properties, leading to
an increase in Duplex Ultrasound (DUS) velocities in the absence
of residual stenosis, many uncertainties remain about the general-
izability of these single-center results with small sample sizes.1
Recently, Pierce et al described disproportionately elevated veloc-
ities for closed cell design when comparing different types of
stents.2 Surprisingly, the authors concluded that their results were
